RxDoctor Payments Data

Thomas O Halloran

Cardiovascular Disease · Boston, MANPI 1922101294

Payments from drug & device makers

$389in general payments, 2019–2025

Across 19 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$128
  • Pfizer$58
  • Boehringer Ingelheim$51
  • AstraZeneca$37
  • Johnson & Johnson$35
  • Actelion Pharmaceuticals US, Inc.$24
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$36894%
  • Education$226%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$389 in reported general payments places this provider in the 30th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$390,001
Medicare patients
2,297
Services billed
5,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$515,053
XareltoRivaroxaban98$113,802
FarxigaDapagliflozin Propanediol74$84,738
EntrestoSacubitril/Valsartan48$77,577
Repatha SureclickEvolocumab37$30,453
BrilintaTicagrelor22$17,853
Praluent PenAlirocumab21$15,371
JardianceEmpagliflozin12$13,135
Metoprolol Succinate413$8,656
Atorvastatin Calcium282$5,765
Torsemide66$1,569
ClopidogrelClopidogrel Bisulfate90$1,422
Valsartan26$1,366
Losartan Potassium114$1,347
Ezetimibe30$1,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$515,053431 claims
Johnson & JohnsonXarelto$35$113,80298 claims
AstraZenecaFarxiga, Brilinta$37$102,59196 claims
NovartisEntresto$128$77,57748 claims
Boehringer IngelheimJardiance$51$13,13512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →